Compare CAVA Group Inc (CAVA) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

CAVA stock surged 12.32% to $69.165, driven by strong Q2 2026 earnings that beat estimates with $0.19 EPS and 31.3% revenue growth. Despite a bearish technical signal, fundamentals show robust expansion with same-store sales up 9% and net income margin at 4.79%. Analyst consensus remains strongly bullish with a $89.75 price target, though high valuations like a P/E of 108.59 pose concerns.

Outlook is positive due to earnings momentum and market share gains, but risks include valuation sensitivity and competitive pressures. Investors should weigh growth potential against premium multiples, with institutional support underscoring long-term confidence amid near-term volatility.

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.